Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Fastnet looks for biotech investments after direction shift

Fastnet had US$15.9mln of cash at the end of July.
Fastnet looks for biotech investments after direction shift
The healthcare industry, particularly the biopharma sector, is experiencing strong momentum.

Fastnet Equity (LON:FAST) has drawn a line under its oil and gas business as it looks for healthcare businesses to acquire.

The company announced the change of direction last month after it struggled to find partners for its hydrocarbon assets in the Celtic Sea and Morocco.

Fastnet has now withdrawn from its involvement in the Foum Assaka Licence, Offshore Morocco and is considering the options for the Irish assets, which may include spinning them off in to a stand-alone entity.

Cash at the end of July was US$15.9mln, while admin costs were down to US$1.9mln per year though the target is to get this down to under US$600,000.

Cathal Friel, chairman, said:The board believes that the healthcare industry, particularly the biopharma sector, is experiencing strong momentum and there exist significant M&A and value creation opportunities for both small cap and large cap companies.

“Furthermore, the board believes that it has access to an international pipeline of such opportunities that could lead to value creation for Fastnet's shareholders.”

Latest figures for the year to March showed an annual loss of US$39.7mln the bulk of which was accounted for by impairments of US$36.6mln for its oil and gas assets.

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Related Articles

picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use